A review in the Journal of Translational Medicine argues that c-MET signaling shapes lung cancer’s immune landscape in a spatially and metabolically constrained way, creating immunosuppressive niches that standard, gene-target-centric strategies may miss. The authors call for combination regimens designed around tumor context rather than single-pathway inhibition. The framing emphasizes that microenvironments differ by location within tumors and that nutrient and metabolic conditions can alter immune cell behavior. By positioning c-MET as a key organizer of those niches, the review points to combination hypotheses that target both signaling and the spatial immunologic barriers it helps build. While reviews are not new trial results, they influence research direction, biomarker selection, and the way combination studies are justified to regulators and funding bodies. For biotech professionals, the actionable signal is the focus shift toward contextual mechanisms—how signaling intersects with metabolism and architecture to drive immune escape.